Initiative for quality in psoriasis and psoriatic arthritis

Journal of Rheumatology

Volumn 35, Issue 7, 2008, Pages 1431-1433

  Boehncke, Wolf Henning ^a   Adebajo, Ade ^b   Cauli, Alberto ^c   Nash, Peter ^d   Salvarani, Carlo ^e   Kavanaugh, Arthur F ^f  

^a GOETHE UNIVERSITY   (Germany)

^b UNIVERSITY OF SHEFFIELD   (United Kingdom)

^c UNIVERSITY OF CAGLIARI   (Italy)

^d Rheumatology Research Unit   (Australia)

^e S MARIA NUOVA HOSPITAL   (Italy)

^f UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Psoriasis; Psoriatic arthritis

Indexed keywords

ADALIMUMAB; CYCLOSPORIN A; ETANERCEPT; GOLD; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; SALAZOSULFAPYRIDINE; STEROID; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

CONFERENCE PAPER; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG EFFICACY; EVIDENCE BASED MEDICINE; HEALTH CARE COST; HEALTH CARE ORGANIZATION; HEALTH CARE QUALITY; HUMAN; MEDICAL SERVICE; PATIENT CARE; PATIENT SAFETY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PSORIASIS; PSORIATIC ARTHRITIS; QUALITY CONTROL; TOTAL QUALITY MANAGEMENT; TREATMENT OUTCOME; UNITED STATES;

ARTHRITIS, PSORIATIC; EVIDENCE-BASED MEDICINE; HUMANS; QUALITY INDICATORS, HEALTH CARE;

EID: 47349123744     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (18)

1. Henseler T, Christophers E. Disease concomitance in psoriasis. J Am Acad Dermatol 1995;32:982-6.
2. 2-macroglobulin plasma activity in medium-severe and severe psoriasis. J Eur Acad Dermatol Venereol 2004;18:180-3.
3. Ludwig RJ, Schultz JE, Boehncke WH, et al. Activated, not resting, platelets increase leukocyte rolling in murine skin utilizing a distinct set of adhesion molecules. J Invest Dermatol 2004;122:830-6.
4. Gelfand JM, Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB. Risk of myocardial infarction in patients with psoriasis. JAMA 2006;296:1735-41.
5. Ludwig RJ, Herzog C, Rostock A, et al. Psoriasis: a possible risk factor for development of coronary artery calcification. Br J Dermatol 2007;156:271-6.
6. Boehncke S, Thaci D, Beschmann H, et al. Psoriasis patients show signs of insulin resistance. Br J Dermatol 2007;157:1249-51.
7. Salvarani C, Lo Scocco G, Macchioni P, et al. Prevalence of psoriatic arthritis in Italian psoriatic patients. J Rheumatol 1995;22:1499-503.
8. Boehncke WH, Brasie RA, Barker J, et al. Recommendations for the use of etanercept in psoriasis: a European dermatology expert group consensus. J Eur Acad Dermatol Venereol 2006;20:988-98.
9. Cauli A, Gladman D, Mathieu A, et al. Patient and physician perception of disease in psoriatic arthritis (PsA). A multicentre GRAPPA and OMERACT study [abstract]. Arthritis Rheum 2007;56 Suppl:S264.
10. Heinen-Kammerer T, Daniel D, Stratmann L, Rychlik R, Boehncke WH. Cost-effectiveness of psoriasis therapy with etanercept in Germany. J Dtsch Dermatol Ges 2007;5:762-8.
11. Olivieri I, de Portu S, Salvarani C, et al. The Psoriatic Arthritis Cost Evaluation (PACE) study: a cost-of-illness study on tumor necrosis factor inhibitors in psoriatic arthritis patients with inadequate response to conventional therapy [abstract]. Arthritis Rheum 2007;56 Suppl:S262.
12. Schoffski O, Augustin M, Prinz J, et al. Costs and quality of life in patients with moderate to severe plaque-type psoriasis in Germany: a multi-center study. J Dtsch Dermatol Ges 2007;5:209-18.
13. Nast A, Kopp IB, Augustin M, et al. Evidence-based (S3) guidelines for the treatment of psoriasis vulgaris. J Dtsch Dermatol Ges 2007;5 Suppl 3:1-119.
14. United Kingdom ARMA Standards of Care. [Internet. Accessed March 11, 2008.] Available from: http://www.arma.uk.net/care.html.
15. Kavanaugh A, Ritchlin C, Boehncke WH. Quality indicators in psoriatic arthritis. Clin Exp Rheumatol 2007;25 Suppl 47:98-101.
16. Mease P. Assessment tools in psoriatic arthritis. J Rheumatol 2008;35:1426-30.
17. Kavanaugh AF, Ritchlin CT. Systematic review of treatments for psoriatic arthritis: an evidence based approach and basis for treatment guidelines. J Rheumatol 2006;33:1417-21.
18. Reich K, Mrowietz U. Treatment goals in psoriasis. J Dtsch Dermatol Ges 2007;5:566-74.